BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 30242519)

  • 1. Migraine and cluster headache - the common link.
    Vollesen AL; Benemei S; Cortese F; Labastida-Ramírez A; Marchese F; Pellesi L; Romoli M; Ashina M; Lampl C;
    J Headache Pain; 2018 Sep; 19(1):89. PubMed ID: 30242519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
    Barbanti P; Aurilia C; Fofi L; Egeo G; Ferroni P
    Neurol Sci; 2017 May; 38(Suppl 1):31-35. PubMed ID: 28527063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.
    Ashina H; Newman L; Ashina S
    Neurol Sci; 2017 Dec; 38(12):2089-2093. PubMed ID: 28856479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review.
    Tfelt-Hansen P; Le H
    J Headache Pain; 2009 Jun; 10(3):137-43. PubMed ID: 19330286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiological role of calcitonin gene-related peptide (CGRP) in migraine and cluster headache].
    Meßlinger K
    Schmerz; 2020 Apr; 34(2):181-187. PubMed ID: 32103345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series.
    Iannone LF; Fattori D; Geppetti P; De Cesaris F
    Neurol Sci; 2022 Jan; 43(1):697-703. PubMed ID: 34586542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptans and CGRP blockade - impact on the cranial vasculature.
    Benemei S; Cortese F; Labastida-Ramírez A; Marchese F; Pellesi L; Romoli M; Vollesen AL; Lampl C; Ashina M;
    J Headache Pain; 2017 Oct; 18(1):103. PubMed ID: 29019093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM; Rapoport AM
    Clin Neuropharmacol; 2017; 40(4):169-174. PubMed ID: 28644160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache.
    Rapoport AM; Edvinsson L
    Neurol Sci; 2019 May; 40(Suppl 1):75-80. PubMed ID: 30906962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack.
    Fanciullacci M; Alessandri M; Figini M; Geppetti P; Michelacci S
    Pain; 1995 Feb; 60(2):119-123. PubMed ID: 7540279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
    Knight YE; Edvinsson L; Goadsby PJ
    Neuropeptides; 1999 Feb; 33(1):41-6. PubMed ID: 10657470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of the trigeminovascular system to nitroglycerine in cluster headache patients.
    Fanciullacci M; Alessandri M; Sicuteri R; Marabini S
    Brain; 1997 Feb; 120 ( Pt 2)():283-8. PubMed ID: 9117375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine.
    Cernuda-Morollón E; Larrosa D; Ramón C; Vega J; Martínez-Camblor P; Pascual J
    Neurology; 2013 Oct; 81(14):1191-6. PubMed ID: 23975872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine.
    Edvinsson L
    Headache; 2017 May; 57 Suppl 2():47-55. PubMed ID: 28485848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.
    Melo-Carrillo A; Strassman AM; Nir RR; Schain AJ; Noseda R; Stratton J; Burstein R
    J Neurosci; 2017 Nov; 37(44):10587-10596. PubMed ID: 28972120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate: Are cluster headache and migraine distinct headache disorders?
    Al-Karagholi MA; Peng KP; Petersen AS; De Boer I; Terwindt GM; Ashina M
    J Headache Pain; 2022 Nov; 23(1):151. PubMed ID: 36447146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromodulation for the Acute and Preventive Therapy of Migraine and Cluster Headache.
    Halker Singh RB; Ailani J; Robbins MS
    Headache; 2019 Jul; 59 Suppl 2():33-49. PubMed ID: 31291017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.